Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.71 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.71 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.71 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757695 | 1.00 | OPRM1 (0.79) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL3766849 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL3766847 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL3766852 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL14993654 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL1706299 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL14653019 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL3765655 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL16449953 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL14653018 | 0.90 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 4/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.